Special Issue

The Role of Mucosal Immune System in Human Health and Disease

Message from the Guest Editor

The purpose of this Special Issue is to disseminate original research and review articles that focus on the cutting-edge knowledge regarding mucosal immune responses. Studies addressing pathophysiological mechanisms and therapeutic strategies related to mucosal immunity are invited. Topics can include, but are not limited to, the following:

- Mechanisms employed by pathogens that can breach the mucosal barrier and compromise immune defence:
- Development of effective mucosal vaccines and novel mucosal adjuvants;
- Novel effector immune components and mechanisms in allergic inflammation;
- Therapeutic strategies that aim to treat and control the development of allergy;
- Autoimmune responses from the perspective of mucosal immunology
- Interaction between the microbiome and mucosal immunity.

Guest Editor

Prof. Dr. Zou Xiang

Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China

Deadline for manuscript submissions

closed (31 August 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/168434

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).